Always think about adding more accounts to ‘drill down’ in the analysis, i.e. have price moved because we’re giving more rebates or volume discounts? I try to add the whole Gross Sales to Margin revenue account structure ‘just in case’

adding a repackaging / ‘creating a comparable’ product functionality that allows you to ‘restate’ the various scenarios to a similar product mix. Replacing a product with a new version of the same product (or a different packaging in pharma) would look like a massive volume impact on the old product, but it’s not necessarily the case. Pharma’s approach at some point is to go to things like ‘per mg of active ingredient / doses / vials’ comparisons

I would avoid doing it in the same part of the model as the other calculations on any decent sized model, a separate reporting cube populated by TIs is the way to go. This analysis requires a lot of C level rules that are caching & performance killers.

unsurprisingly we couldn’t standardise this calculation even for different country branches of the same company and it’s still a hard thing starting from a template model, C-level rules will do your head in